KOL Investor Event - SOL-GEL TECHNOLOGIES LTD

Explicit Guidance:

• Topline Data Release: Expected next month (post-Q4 context).
• Regulatory Milestones: New Drug Application (NDA) submission targeted for April; regulatory approval anticipated in Q2 2026 (approx. 6 months post-NDA) leveraging orphan drug and breakthrough therapy designations.
• Commercial Launch: United States market launch scheduled for the beginning of 2028.
• Intellectual Property: Strong IP protections expected to last until at least 2045.
• Financial Projections: Peak sales forecast targets 65% market penetration of an estimated 4,000 patients (derived from 860,000 price-adjusted eligible patients in the US), aiming for a peak revenue run rate of $1 billion.
• Operational Targets: Commercialization team size estimated at 20 FTEs (sales reps/assays); expected to reach profitability at a reasonable patient volume due to high product price and contribution margins.

Business-Segment Outlook:

• Core Indication: Primary focus remains on Gorlin syndrome (Basal Cell Carcinoma [BCC] prevention and reduction) for the immediate future.
• Expansion Pipeline:
  • Geographic Expansion: US launch first ("America First"), with international markets (Europe/Rest of World) planned for partnership/licensing post-US success due to complex pricing landscapes.
  • Disease Extensions: Future indications under exploration include "high-frequency BCC" (non-Gorlin patients) and pediatric populations, contingent on accumulating safety data regarding height growth.
  • Application Expansion: Development of new topical applications for the entire body (beyond the face) to address sun-exposed areas (scalp, neck, hands, legs).
  • Neoadjuvant Therapy: Launching a study this month to assess SGT 610 for downsizing BCCs (approx. 50% reduction) in sensitive facial areas prior to surgical excision.
• Patient Selection Strategy: Post-hoc analysis suggests drug efficacy is consistent regardless of baseline BCC count (2 vs. 10+), though study design currently targets patients with 10+ BCCs to maximize statistical power by leveraging higher placebo response rates in severe disease.
• Adherence Targets: Aiming for 80% patient adherence through direct patient support and integration with the Gorlin Syndrome Alliance (GSA) to maintain chronic usage.

Market and Competitive Outlook:

• Market Size: US target population estimated at 600,000 eligible patients after conservative filtering; peak utilization of 4,000 patients projected.
• Competitive Advantage: SGT 610 positions as a first-in-class topical hedgehog inhibitor offering high efficacy comparable to oral inhibitors (Vismodegib/Vismotigib) but without systemic side effects (hair loss, taste changes, muscle cramps), targeting a market currently underserved by oral tolerability issues.
• Pricing Strategy: Pricing expected to be comparable to other expensive topical drugs, positioned at roughly half the price of oral hedgehog inhibitors, challenging the historical low-price categorization of topicals.
• Adoption Trajectory: Management anticipates rapid uptake due to high unmet need, physician familiarity with hedgehog mechanisms, and patient demand for a non-toxic preventive option; 94% of surveyed patients indicated a 30% reduction in new BCCs with no side effects would be a preferred treatment.
• Commercial Model: Independent US commercialization via a lean team targeting ~200 centers of excellence, avoiding licensing deals to retain economics; international markets likely to be handled via partners.

Macro / Industry Outlook:

• Regulatory Environment: FDA has explicitly recommended a new, adequately powered trial but acknowledged the potential to modify study designs to include broader populations or sensitive subgroups.
• Patient Awareness: Anticipated surge in disease awareness and new diagnoses ("uprise") once a therapy becomes available, previously driven by lack of treatment options.
• Pricing Dynamics: US pricing independence from Europe to avoid downward pressure on global revenues; European market dynamics complicated by price controls.
• Regulatory Precedent: Management notes that FDA "enrichment" strategies (requiring high BCC counts for trials) have not historically restricted label indications to those same high-burden patients, expecting a broader label post-approval.

Strategic Initiatives:

• Clinical Trial Refinements: Transitioned from Pelopharm's Phase 3 (10 BCC baseline, PTCH1 not mandatory) to Solgel's optimized design (10+ facial BCC, PTCH1 mandatory, dermoscopy required, central photography review board, reduced visits from many to 6).
• Patient Support Infrastructure: Collaborating with the Gorlin Syndrome Alliance (GSA) to establish regional centers of excellence and integrate patient tracking; proactive application for specific ICD codes for Gorlin syndrome.
• Safety Monitoring: Initiating gradual inclusion of pediatric patients (closer to normal height) once additional safety data is accumulated to mitigate growth stunting risks associated with hedgehog inhibitors.
• Capacity Building: R&D and clinical teams operating with 10% patient dropout rates in the current trial (significantly lower than industry averages) due to enhanced patient monitoring and protocol rigor.

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: FDA discretion remains; approval dates and final labeling are not guaranteed despite orphan/breakthrough designations.
• Safety Concerns: Potential for teratogenicity and growth stunting in pediatrics; systemic absorption concerns (though topical absorption is estimated at 1/100th of oral levels).
• Adherence Risks: Chronic nature of disease may lead to patient disengagement or non-adherence despite support programs.
• Study Design Interpretation: Reliance on post-hoc analysis and placebo response dynamics in lower-burden populations could impact future trial success if not replicated.
• Geopolitical/Pricing: Potential for lower pricing in international markets compared to the US could impact global revenue forecasts; reliance on partners in international markets introduces execution risk.
• Scientific Validation: The hypothesis that "no growth in placebo" for mild disease is a study artifact rather than a biological truth could limit trial power if the placebo group in real life demonstrates higher growth rates.

Management Tone on the Future:

• Confidence Level: Highly confident and bullish; expressed strong belief that the drug will be a "success" and an "iron wall" against competition.
• Strategic Shift: Demonstrated decisive pivot from Pelopharm's failed statistical approach to a targeted, enriched patient population to capture the drug's full protective effect.
• Vision: Management views SGT 610 as a "life-changing" breakthrough that could significantly reduce the surgical burden (aiming for 30-50% reduction in new BCCs and surgeries) and improve quality of life, potentially rendering future Mohs surgeries less frequent.
• Market Positioning: Aggressive "America First" approach reflects belief in the company's ability to commercialize independently in a specialized niche, contrasting with the "bleed" model of other orphan drug companies.

Miscellaneous:

• Study Parameters: Current trial enrolled 113 patients across 41 sites; 102 completed (10% dropout rate). Primary endpoint: number of new BCCs. Key secondary endpoint: number of new surgically eligible BCCs.
• Genetic Subgroups: Approx. 80% of Gorlin patients are PTCH1 positive (highly responsive to hedgehog inhibitors); ~5% are SUFU positive (potential resistance due to downstream mutations); ~10-15% of unknown etiology.
• Physician KOL Consensus: Leading dermatologists and surgeons anticipate rapid adoption and view the drug as a preferred alternative for the majority of moderate-to-high burden patients, potentially replacing or supplementing oral hedgehog inhibitors.